Cryptococcal Meningitis
33
4
4
16
Key Insights
Highlights
Success Rate
89% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
6.1%
2 terminated out of 33 trials
88.9%
+2.4% vs benchmark
27%
9 trials in Phase 3/4
31%
5 of 16 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 16 completed trials
Clinical Trials (33)
Etiology, Pathogenesis, and Natural History of Idiopathic CD4+ Lymphocytopenia
Fungal Infection Susceptibility
Single Dose Liposomal Amphotericin for Asymptomatic Cryptococcal Antigenemia
Platform Trial For Cryptococcal Meningitis
Optimizing the Dose of Flucytosine for the Treatment of Cryptococcal Meningitis
Amphotericin B for Non-HIV Cryptococcal Meningitis Patients
Encochleated Oral Amphotericin for Cryptococcal Meningitis Trial (EnACT)
Point of Care Tests to Identify Opportunistic Infections in Advanced HIV Patients in Mexico City
Encochleated Oral Amphotericin for Cryptococcal Meningitis Trial 3
Clinical Study of ABCD in the Treatment of Cryptococcal Meningitis
Driving Reduced AIDS-associated Meningo-encephalitis Mortality
Clinical Effectiveness and Safety of Amphotericin B With Flucytosine-Fluconazole Therapy for Cryptococcal Meningitis
The Lived Experience of Participants in an African Randomised Trial
High-Dose Fluconazole for the Treatment of Cryptococcal Meningitis in HIV-Infected Individuals
Three Induction Treatments on Cryptococcal Meningitis
Cryptococcal Optimal ART Timing Trial
Adjunctive Sertraline for the Treatment of HIV-Associated Cryptococcal Meningitis
Operational Research for Cryptococcal Antigen Screening
AmB Dose for Cryptococcal Meningitis
CryptoART Study: Decreasing Mortality Associated With Initiation of Antiretroviral Therapy in Sub-Saharan Africa